Teriflunomide

證據等級: L5

預測適應症: 1 個

Teriflunomide: From No Registered Indication to Relapsing-Remitting Multiple Sclerosis

One-Sentence Summary

Teriflunomide (Aubagio®) is an oral immunomodulator — the active metabolite of leflunomide — that selectively inhibits lymphocyte proliferation via mitochondrial DHODH enzyme blockade, and currently holds no registered local indication in this market.

The TxGNN model predicts it may be effective for relapsing-remitting multiple sclerosis (RRMS), with 28 clinical trials and 19 publications currently supporting this direction — including multiple completed Phase 3 pivotal trials that establish it as a benchmark comparator for emerging MS therapies.

Quick Overview

Item	Content
Original Indication	No locally registered indication
Predicted New Indication	Relapsing-Remitting Multiple Sclerosis (RRMS)
TxGNN Prediction Score	99.24%
Evidence Level	L1
Market Status	Not Marketed (0 registered licenses)
Number of Licenses	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Teriflunomide is the active metabolite of leflunomide, exerting its therapeutic effect by selectively and reversibly inhibiting dihydroorotate dehydrogenase (DHODH), a mitochondrial enzyme essential for the de novo synthesis of pyrimidines. Because rapidly proliferating lymphocytes — unlike most resting cells — depend heavily on this biosynthetic pathway, teriflunomide preferentially suppresses the expansion of autoreactive T and B cells without broad immunosuppression. In the context of RRMS, this mechanism directly addresses the pathological cycle of immune-mediated demyelination and inflammatory lesion formation in the central nervous system.

The biological rationale connecting teriflunomide to RRMS is not speculative but mechanistically established. RRMS is driven by episodic activation and clonal expansion of myelin-reactive lymphocytes that breach the blood–brain barrier and trigger focal inflammatory attacks. By depleting the pyrimidine pool selectively in dividing cells, teriflunomide attenuates this cascade at the source — reducing relapse frequency, suppressing new MRI lesion formation, and slowing disability accumulation, as demonstrated in multiple Phase 3 trials.

Although the evidence pack records the local MOA field as unavailable, the DHODH-inhibition mechanism is comprehensively established in the international literature. Multiple pivotal trials (including NCT00134563 with n = 1,088) confirm approximately 31–36% relapse rate reduction versus placebo, and the drug now serves as the standard active comparator in Phase 3 trials for next-generation MS therapies including ofatumumab, ublituximab, ponesimod, evobrutinib, and tolebrutinib. The TxGNN model score of 99.24% reflects this robust mechanistic-epidemiological alignment.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00134563	Phase 3	Completed	1,088	Pivotal RCT evaluating teriflunomide (7 mg and 14 mg) vs. placebo in relapsing MS. Primary endpoint: annualized relapse rate. Secondary: EDSS disability progression, MRI lesion burden, patient-reported fatigue. Represents core L1 registration evidence (~31–36% relapse reduction).
NCT00883337	Phase 3	Completed	324	Randomized rater-blinded multicenter study comparing two doses of teriflunomide vs. interferon beta-1a on time to treatment failure in relapsing MS, with long-term extension. Assessed relapse frequency, fatigue, and patient satisfaction.
NCT00803049	Phase 3	Completed	742	Long-term extension of the multinational Phase 3 EFC6049 trial. Primary objective: document long-term safety and tolerability of teriflunomide 7 mg and 14 mg. Secondary: long-term disability progression, relapse rate, and MRI parameters.
NCT04788615	Phase 3	Completed	185	Open-label rater-blinded randomized study comparing ofatumumab 20 mg SC monthly vs. physician’s choice first-line DMT (including teriflunomide) in newly diagnosed relapsing MS patients.
NCT00228163	Phase 2	Completed	147	Long-term extension of Phase 2 safety and efficacy study (HMR1726D/2001). Evaluated long-term safety and tolerability of teriflunomide in relapsing MS over more than a decade.
NCT02490982	N/A	Completed	106	Investigator-initiated real-world effectiveness study of teriflunomide in RRMS patients treated in regular clinical practice over at least two years at a dedicated MS clinic.
NCT04129736	Phase 4	Completed	12	Pharmacokinetic study measuring teriflunomide concentrations in serum and cerebrospinal fluid from RRMS patients on 14 mg daily dosing, informing CNS penetration and exposure-response relationships.
NCT01881191	N/A	Completed	50	Prospective single-blinded longitudinal MRI study evaluating the effect of teriflunomide (Aubagio®) on gray matter pathology over 12 months, providing imaging biomarker evidence for neuroprotective potential.
NCT03561402	N/A	Completed	24	Two-year prospective observational study assessing putative biomarkers for disease activity prediction in RRMS patients receiving teriflunomide, informing pharmacodynamic monitoring strategies.
NCT04676204	N/A	Enrolling by Invitation	323	STATURE: Prospective multi-site study measuring treatment burden and adherence across six oral DMTs including teriflunomide, dimethyl fumarate, fingolimod, cladribine, ozanimod, and diroximel fumarate. Provides real-world comparative adherence data.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
38174776	2024	Network Meta-Analysis	Cochrane Database of Systematic Reviews	Updated Cochrane NMA comparing immunomodulators and immunosuppressants for RRMS. Synthesizes relative efficacy of teriflunomide vs. all available DMTs on relapse frequency and disability accumulation.
32757523	2020	RCT (Phase 3 Head-to-Head)	New England Journal of Medicine	ASCLEPIOS I & II: Ofatumumab vs. teriflunomide in relapsing MS (n > 1,800). Ofatumumab demonstrated superior MRI and clinical outcomes; teriflunomide arm establishes benchmark comparator efficacy.
40202623	2025	RCT (Phase 3 Head-to-Head)	New England Journal of Medicine	Tolebrutinib (oral BTK inhibitor) vs. teriflunomide in relapsing MS. Demonstrates teriflunomide’s continued role as active comparator in next-generation Phase 3 trial design.
36001711	2022	RCT (Phase 3 Head-to-Head)	New England Journal of Medicine	Ublituximab vs. teriflunomide in relapsing MS. Ublituximab (enhanced B-cell depletion) showed superior MRI outcomes; confirms teriflunomide’s established efficacy as standard comparator.
39307151	2024	RCT (Phase 3 Head-to-Head)	The Lancet Neurology	evolutionRMS1 and evolutionRMS2: Evobrutinib vs. teriflunomide across two Phase 3 trials. Teriflunomide arm provides contemporary real-world comparator data across multinational sites.
33779698	2021	RCT (Phase 3 Head-to-Head)	JAMA Neurology	OPTIMUM trial: Ponesimod vs. teriflunomide — first Phase 3 study comparing two oral DMTs for relapsing MS. Ponesimod showed superiority on ARR; teriflunomide arm performance characterizes real-world standard-of-care.
33620411	2021	Review	JAMA	Comprehensive review of MS diagnosis and treatment for 900,000 affected US patients. Summarizes current evidence base including teriflunomide’s role as oral first-line DMT.
31098896	2019	Systematic Review / Drug Review	Drugs	Dedicated teriflunomide review: mechanism (DHODH inhibition → de novo pyrimidine synthesis blockade → selective lymphocyte antiproliferation), RCT evidence synthesis, and real-world safety profile.
37691530	2023	Long-term Extension Study	Multiple Sclerosis	ALITHIOS extension: ofatumumab demonstrated superior efficacy and favorable safety vs. teriflunomide over 4 years in relapsing MS. Provides 4-year longitudinal teriflunomide comparator data.
31898276	2020	Systematic Review	CNS Drugs	Narrative review comparing five oral DMTs for RRMS — fingolimod, dimethyl fumarate, teriflunomide, cladribine, and siponimod — on relative efficacy and safety. Contextualizes teriflunomide’s positioning in the oral therapy landscape.

Market Information

No licenses are currently registered in the local regulatory database for teriflunomide. The drug is marketed internationally as Aubagio® (Sanofi) and holds regulatory approval for relapsing forms of multiple sclerosis from both the US FDA (approved 2012) and the European Medicines Agency, as evidenced by its consistent role as the active comparator across more than five global Phase 3 trials conducted between 2020 and 2025. A formal local registration application would be required before clinical availability.

Safety Considerations

Local safety data (package insert warnings, contraindications, and drug interaction database) are not available in the current evidence pack.

Please refer to the internationally approved package insert (Aubagio® US Prescribing Information / EMA SmPC) for full safety information, which includes hepatotoxicity monitoring requirements, teratogenicity risk with mandatory accelerated elimination protocol, and lymphopenia management guidance.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Teriflunomide’s efficacy in RRMS represents one of the most thoroughly validated drug-indication pairs in modern neurology: multiple completed Phase 3 RCTs (including a 1,088-patient pivotal trial), a Cochrane NMA, and consistent use as an active comparator across five additional Phase 3 trials published between 2020 and 2025 collectively establish L1 evidence with no meaningful scientific uncertainty about biological plausibility. The TxGNN model score of 99.24% correctly reflects this convergence. The primary barrier to deployment is regulatory and logistical rather than scientific.

To proceed, the following is needed:

Regulatory filing: Submit a New Drug Application (or equivalent local regulatory pathway) with the pivotal trial package (NCT00134563 and NCT00883337 extension data) as core dossier
Local safety data collection: Obtain and review the full Aubagio® US Prescribing Information and EMA SmPC; extract hepatotoxicity monitoring protocol, teratogenicity risk management (mandatory pregnancy prevention program and accelerated elimination procedure with cholestyramine/activated charcoal), and lymphocyte count monitoring thresholds
Drug interaction profile: Conduct formal DDI review given known CYP2C8 inhibition and potential interactions with warfarin, repaglinide, and hormonal contraceptives
Risk management plan: Establish a local Risk Minimization Measure (RMM) program aligned with international REMS requirements, particularly for women of childbearing potential
Post-marketing surveillance plan: Define monitoring parameters for hepatic enzyme elevation (ALT/AST), lymphopenia, blood pressure, and peripheral neuropathy consistent with international labeling
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.